IMU-838

October 9, 2019October 9, 2019

Interim Analysis Suggests Wider-than-expected Dosing Range for IMU-838 to Treat Ulcerative Colitis

News

Interim analysis of a Phase 2 clinical trial that’s investigating IMU-838 in people with ulcerative colitis (UC) suggests a broader dose range than initially anticipated, announced the therapy’s developer, Immunic ... Read more

July 1, 2019July 1, 2019

Therapy Candidate IMU-838 Shows Strong Activity in Preclinical Models of UC, Immunic Announces

News

IMU-838, Immunic Therapeutics‘ lead therapy candidate for the treatment of ulcerative colitis (UC) and relapsing-remitting multiple sclerosis (RRMS), shows strong activity in cellular and animal models of disease, preclinical studies ... Read more

May 4, 2018May 4, 2018

Immunic Starts Enrollment in Phase 2 CALDOSE-1 Clinical Trial

News

The first patient has enrolled in the CALDOSE-1 phase 2 clinical trial, which seeks to determine whether Immunic AG‘s investigational drug IMU-838 can induce and maintain remission in patients with active ... Read more

January 15, 2018

FDA OKs Application for Immunic’s UC Therapy, Green-lighting Phase 2 Trial

News

The U.S. Food and Drug Administration has cleared the way for Immunic Therapeutics to begin a Phase 2 trial testing IMU-838, its therapy candidate for ulcerative colitis. The FDA’s approval of Immunic’s investigational new drug ... Read more